MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study

Jahr

2014

Autoren

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Ziemssen T, Duda P; RESTORE.

Verlag

Neurology. 2014 Apr 29;82(17):1491-8.

Link

https://doi.org/10.1212/wnl.0000000000000355

MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Higher effect sizes for the detection of accelerated brain volume loss and disability progression in multiple sclerosis using deep-learning